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Abstract Introduction: The Age-Well clinical trial is an ongoing monocentric, randomized, controlled trial1These authors co
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license (http://creativeaiming to assess an 18-month preventive meditation-based intervention directly targeting the atten-
tional and emotional dimensions of aging to promote mental health and well-being in elderly people.
Methods: One hundred thirty-seven cognitively unimpaired older adults are randomized to either an
18-month meditation-based intervention, a structurally matched foreign language training, or a pas-
sive control arm. The impact of the intervention and underlying mechanisms are assessed with
detailed cognitive, behavioral, biological, neuroimaging and sleep examinations.
Results: Recruitment began in late 2016 and ended in May 2018. The interventions are ongoing and
will be completed by early 2020.
Discussion: This is the first trial addressing the emotional and cognitive dimension of aging with a
long-term nonpharmacological approach and using comprehensive assessments to investigate the
mechanisms. Results are expected to foster the development of preventive strategies reducing the
negative impact of mental conditions and disorders.
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As the number of older people grows, increasing healthy
life years is a priority. The main drivers of decreased mental
health and well-being in aging populations include demen-
tia, depression, anxiety, insomnia, and even subclinical con-
ditions such as stress, worry, sleep disturbances, and
cognitive decline [1,2]. Moreover, these conditions interact
and promote each other. For instance, anxiety, depression,
and sleep difficulties are associated with increased risk of
Alzheimer’s disease (AD).
The reduction of modifiable risk factors represents a true
opportunity to prevent AD [3,4]. Indeed, around a third of
AD cases may be attributable to potentially modifiable risk
factors, and the future prevalence of AD could be reduced
by 8% to 15% if each of the main risk factors (e.g.,
cardiovascular risk factors, depression, physical, and
cognitive inactivity) is reduced by 10 to 20% [3,5]. Several
lifestyle interventions in nondemented older adults have
thus been investigated with mixed results before larger-
scale trials with long-term (.1 year) follow-up and using
multidomain interventions simultaneously targeting various
risk factors were launched [6]. Examples of such multido-
main prevention randomized controlled trials (RCTs)
include the Multidomain Alzheimer Prevention Trial
(MAPT) [7], the Finnish Geriatric Intervention Study to Pre-
vent Cognitive Impairment and Disability (FINGER) trial
[8], and the Prevention of Dementia by Intensive Vascular
Care (PreDIVA) trial [9]. Positive effects on cognitive func-
tion were found in Finnish Geriatric Intervention Study to
Prevent Cognitive Impairment and Disability [10], which
has evolved toward a worldwide consortium, World Wide
Finnish Geriatric Intervention Study to Prevent Cognitive
Impairment and Disability, including, for example, the
U.S. equivalent U.S. POINTER (https://alz.org/us-pointer/).
These trials target most of the main modifiable risk factors
(cardiovascular risk factors, physical and cognitive inac-
tivity). Yet although very important, psychoaffective risk fac-
tors have so far not been directly targeted.
A promising way of targeting psychoaffective risk factors
consists in mental training for the reduction of stress, the
regulation of attention and the cultivation of positive emo-
tions through meditation practice. Such interventions might
be beneficial to improve mental health and well-being in the
aging population and reduce AD risks. Promising evidence
exists that mindfulness meditation improves cognition in
young adults (mainly attention, metacognition and memory,
which are cognitive processes sensitive to aging and AD)
[11–13], and reduces stress, anxiety, depression, insomnia
[14–17] and cardiovascular risk factors [18,19]. Moreover,
meditation has also been associated with brain structural
and functional changes that persist beyond the time of
actual practice and mainly impact frontal and limbic
networks [20–23]. In a recent cross-sectional pilot study,
we showed that elderly expert meditators had higher gray
matter volume and/or fluorodeoxyglucose metabolismcompared with age-matched non-meditators in frontal,
insula and posterior associative regions [24]. These findings
suggest that meditation might have a beneficial effect in
brain regions sensitive to aging and AD and subtending
reserve processes, thereby reducing the risk or delaying
the onset of dementia/AD.
To test this hypothesis, we need an RCT including an
adequate active control comparison condition to estimate
the specific effects of a meditation intervention. The dura-
tion of the intervention should exceed that of the commonly
used 8-week mindfulness-based stress reduction program to
demonstrate an effect not only on behavioral, but also on
protracted age-related biological processes. Moreover, com-
plementary outcome measures allowing to investigate the
mechanisms of action and to assess the multidimensional
aspect of aging should be used.
Medit-Ageing (public name: Silver Sante Study; www.
silversantestudy.eu) is a European research project focusing
on mental health and well-being in aging populations. It in-
cludes two independent clinical studies (SCD-Well and
Age-Well) and the Age-Well study includes an RCT and
an observational cross-sectional study on older expert
long-term meditators. The present article will focus on the
design and progress of the Age-Well RCT.
The Age-Well RCT is the first trial addressing the
emotional and cognitive dimension of aging with a long-
term nonpharmacological approach and including both an
active and a passive control conditions. A complete set of
unique measurements will be used to investigate the mecha-
nisms of action, including cognitive tests particularly
focusing onmemory and attention, scales and questionnaires
assessing well-being, quality of life, psychoaffective factors
and lifestyle, but also complementary neuroimaging mea-
sures of brain structural and functional integrity, emotion
and attention-related neural activity, biological blood
measures and gold-standard measures of sleep with poly-
somnography. Finally, on the level of social relations, mea-
surements in participants’ partners will allow to investigate
their perception of the participant’s changes and their own
perceived social support. Objective biomarkers of brain
integrity will be used as primary outcomes.
Wehypothesize thatmeditation trainingwill be associated
with an increase in positive emotions and improved cognitive
control which will in turn enhance health andwell-being, and
promote brain and cognitive reserve processes that are pro-
tective of dementia. Qualitative and quantitative differences
are expected in the effects of meditation versus foreign lan-
guage training interventions as they are thought to involve
overlapping but partly distinct mechanisms (Fig. 1).
2. Methods/design
2.1. Clinical trial setting and design
The Age-Well clinical trial is a monocentric, randomized,
controlled superiority clinical trial with blinded endpoint
assessment and with three parallel arms: an 18-month
Fig. 1. Hypothetical model of the expected effects and mechanisms of the
meditation and foreign language training interventions included in the Age-
Well RCT. Meditation training is thought to promote both emotional regu-
lation/positive affect and cognitive control. Foreign language training is
expected to act mainly through cognitive stimulation. Consequently, while
both themeditation and foreign language training interventions are expected
to have a positive impact on markers of mental health and well-being in ag-
ing, the nature and degree of these effects are expected to differ between
both interventions. Abbreviations: EEG, electroencephalography; ERP,
event-related potential; FDG, fluorodeoxyglucose; MRI, magnetic reso-
nance imaging; PET, positron emission tomography.
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training intervention arm (the active control) and a no-
intervention passive control arm. The Age-Well RCT in-
cludes 137 cognitively unimpaired older adults. Participants
were recruited in three successive cohorts of 43, 50 and 44
participants, respectively, spaced about 6 months apart.
The general design of the trial is depicted in Fig. 2 and the
different steps are detailed in the Supplementary Material.
In brief, participants were recruited from the general popula-
tion, prescreened, and then invited to a screening visit (V0)
at which the diagnostic battery depicted in Table 1 was per-
formed. Participants fulfilling eligibility criteria (Table 2)
were invited to the baseline pre-intervention visit (V1),
then randomized to one of the three arms (groups) at a ratio
of 1:1:1, and the 18-month intervention period starts. A mid-
intervention intermediate visit (V2) is performed 9 months
after the start of the intervention, and the post-intervention
visit (V3) is performed at the end of the 18-month interven-
tion period.
2.2. Measures collected at the baseline and follow-up
visits (V1, V2, and V3)
V1 and V3 comprise a multidisciplinary assessment of
awide range of behavioral and biological measures collected
within a maximum of 3 months before (V1) and after(V3) the start of the intervention. The detailed biological,
behavioral, neuroimaging and sleep measures collected at
the pre-intervention and post-intervention visits (V1 and
V3) are listed in Table 3; the mid-intervention intermediate
visit (V2) includes a selected set of the behavioral measures
collected at V1 and V3 as indicated in Supplementary
Table 1. Briefly, behavioral measures are neuropsychologi-
cal tests assessing different cognitive functions (e.g. episodic
memory, attention, executive function), scales and question-
naires assessing, for example, sleep quality, lifetime and cur-
rent engagement in cognitive, social and physical activities;
Mediterranean diet adherence, health-related behaviors such
as self-medication, smoking and alcohol consumption, qual-
ity of life and well-being, psychoaffective factors such as
anxiety and depression, and prosocialness (Supplementary
Table 1 for details). Some of the questionnaires are also
given to a participant’s close relative or friend (subsequently
referred to as the “partner”). Neuroimaging measures
include a series of structural and functional (resting-state
and task-related) MRI scans, fluorodeoxyglucose (Glucotep)
and florbetapir (AV45, Amyvid) positron emission tomogra-
phy scans, and resting-state electroencephalography and
auditory event related potential recording (Supplementary
Table 2 for details). Objective measures of sleep include ac-
tigraphy, an ambulatory monitoring device using heart rate
and body movements to score sleep (SomnoArt) and poly-
somnography. Biological measures are obtained from blood
sampling (Supplementary Table 3). All procedures for data
acquisition were discussed and audited by experienced
and skilled study staff to ensure standardization of the
procedures.2.3. Interventions
The 18-month intervention period starts just after the
randomization step for each of the three cohorts of 43, 50,
and 44 participants, each subdivided in three groups (medi-
tation, foreign language, control) of 14–17 participants.
During the study, participants are strongly encouraged not
to practice the activity proposed in the other arms (groups).
The meditation and the foreign language training interven-
tions are structurally equivalent in overall course length, class
time, and home activities and matched in administration,
dosage, and duration. The number of teachers per class and
their level of expertise are equal in both interventions. Partic-
ipants are encouraged to participate in all those activities dur-
ing the whole period of the intervention (i.e., 18 months).
In addition to being structurally equivalent, we actively
tried to balance researcher allegiance to the two interven-
tions as this might have significant impact on the findings
[4–6,32,33]. A well-designed control should also include a
rationale for the positive expectation for intervention suc-
cess by both the teachers and participants [34]. We thus tried
to keep all communications about the study fully balanced as
regard to expected effects of both the meditation and the
foreign language training interventions and underpinning
Fig. 2. Flow chart of the Age-Well RCT participants. The different steps are detailed in the text. The boxes at V1 and V3 depict the types of measurements that
are collected. Abbreviation: RCT, randomized controlled trial.
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pectations regarding the intervention, a questionnaire was
proposed to them at the beginning of the intervention (Cred-
ibility and Expectancy questionnaire, [35]).
For both the meditation-based and the foreign language
training interventions, participants follow:
- 2-hour weekly group sessions,
- daily home practice (at least 20 minutes per day),
- one day of more intense practice during the interven-
tion (5 hours during the day).
Both interventions have been fully described a priori in
respective manuals.Table 1
Tests included in the diagnostic battery performed during the screening visit V0
Diagnostic battery
Domains evaluated Tests Score
Manual laterality Edinburgh Questionnaire Uniq
Global cognitive functioning MMSE Uniq
Depression Montgomery and Asberg Depression
Rating Scale
Uniq
Executive functions Wisconsin Card Sorting Test Mult
Verbal episodic memory RL-RI16 Mult
English test Evaluation of oral and written
comprehension.
UniqThe meditation intervention consists of an original
secular program of meditation training labeled “The Silver
Sante Study Meditation Programme” especially designed
for this study based on pre-existing interventions (as detailed
in the Supplementary Materials) with the objective of per-
sonal development and healthy aging, and is provided by
expert meditator instructors in Caen. The objective of this
18-month intervention program is to develop mindfulness,
kindness and compassion abilities as additional psychologi-
cal resources to cope with challenges related with aging on
physical, cognitive and psychological aspects. The first 9
months of the intervention are dedicated to the teaching of
mindfulness meditation whereas the 9 following months(s) References Expected performances
ue [25] Not applicable
ue [26] Norms according to age, sex, and education level
ue [27] Score , 19
iple [28] Z score . 21.65 (norms according to age, sex,
and education level)
iple [29] Z score . 21.65 (norms according to age, sex,
and education level)
ue Original test Score ,16/18
Table 2
Inclusion and exclusion criteria for the Age-Well clinical trial
Inclusion criteria Exclusion criteria
- Age 65 years
- Autonomous
- Living at home
- Educational level 7 years (from the Preparatory Course—1st
grade—included)
- Registered to the social security system
- Motivated to effectively participate in the project and signing the
informed consent form
- Performance within the normal range on standardized cognitive tests
according to agreed study-specific standards (age, sex and education
level when available)
- Native French speaker
- Available to attend the intervention for the trial duration (24 months)
- Retired for at least one year
- No strong preference or aversion for an intervention group
- No present or past regular or intensive practice of meditation or
comparable practices; the practice is considered as regular and/or
intensive if i) it occurs more than one day per week for more than six
consecutive months over the last 10 years, and/or in case of more than
five consecutive days of intensive practice (internship or retreat) over
the past 10 years, and/or of more than 25 days of retreats (cumula-
tively) within the last 10 years
- Not speaking fluent English
- Safety concerns in relation to MR scanning (claustrophobia, ferro-
magnetic object) or PET scanning (blood sampling to check hepatic
and renal functions are performed before the PET scans; known hy-
persensibility to Amyvid or Glucotep)
- Presence of a major neurological or psychiatric disorder (including an
addiction to alcohol or drugs)
- History of cerebral disease (vascular, degenerative, physical malfor-
mation, tumor, or head trauma with loss of consciousness for more
than an hour)
- Presence of a chronic disease or acute unstable illness (respiratory,
cardiovascular, digestive, renal, metabolic, hematologic, endocrine or
infectious)
- Current or recent medication that may interfere with cognitive func-
tioning (psychotropic, antihistaminic with anticholinergic action, anti-
Parkinson’s, benzodiazepines, steroidal anti-inflammatory long-term
treatment, antiepileptic or analgesic drugs), the interfering nature of
the different treatments being at the discretion of the investigating
doctor
- Being under legal guardianship or incapacitation
- Participation in another biomedical research protocol including the
injection of radiopharmaceuticals
- Physical or behavioral inability to perform the follow-up visits as
planned in the study protocol
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kindness and compassion. Each session contains moments
of group meditation, sitting, or walking and moments of
sharing and teaching.
The foreign language training program is a cognitively stim-
ulating intervention structurally matched to the meditation
intervention and hypothesized to have no specific effect on
emotional measures. It consists of English exercises designed
to reinforce eachparticipant’s abilities in understanding,writing
and speaking. Sessions are held by mixing oral comprehension
and expression activities to work in priority, the acquisition of
new vocabulary and new grammatical structures.
Participants in the passive control group are requested not
to change their habit and continue living as they used to
before engaging in the study and until the end of V3. They
are specifically asked not to engage in meditation or foreign
language training.
More details on the interventions can be found in the
Supplementary Material.2.4. Outcome measures
The main objective of the Age-Well RCT is to test,
whether an 18-month meditation-based intervention in
cognitively unimpaired older adults is superior to i) a passive
control group on changes in volume and perfusion of the
anterior cingulate cortex (ACC); ii) an 18-month foreign lan-
guage training program on changes in volume and perfusion
of the insula. Accordingly, the primary outcomes are the
mean change in the volume and perfusion of both the ACC
and the insula, as measured with structural T1-weightedMRI and early florbetapir positron emission tomography
scan respectively from the baseline pre-intervention to the
18-month post-intervention follow-up visits.
The secondary objectives will focus on the effects of the
interventions on cognition, well-being, quality of life,
psychoaffective factors and lifestyle; complementary
neuroimaging measures of brain integrity, emotion and
attention-related neural activity; sleep quality with polysom-
nography; and biological blood measures in the aging popu-
lation. Sex-specific effects of the interventions and effects on
participants’ partners (perception of participant’s changes
and their own perceived social support) will also be assessed,
together with exploratory analyses unrelated to the clinical
trial intervention (e.g., aiming to further understand the
impact of lifestyle factors and the physiopathological mech-
anisms of AD). The secondary outcomes used to assess these
questions are listed in Table 3. Adverse events and measures
collected during the intervention by the teachers and
self-report of participants will be used to assess safety,
acceptance and adherence.2.5. Statistical considerations2.5.1. Sample size calculation
The comparison of the meditation versus passive control
arms will focus on the mean change in (1) volume and (2)
perfusion of the ACC from the baseline pre-intervention visit
to the end of the 18-month intervention, with an expected
relevant effect size of 0.75, as suggested by a meta-
analysis of meditation effects on neuroimaging markers
Table 3
List of collected measures and corresponding outcomes
Measures collected at V1 and V3 (and V2 for a selected set of behavioral
measures) Outcomes
Behavioral measures (Supplementary Table 1 for details):
Series of neuropsychological tests,scales and questionnaires selected as
they are particularly sensitive to aging and AD (e.g., assessing
episodicmemory, attention, executive functions and metacognition)
and/or meditation practices (e.g., assessing mindfulness, compassion,
and interoception), emotions (e.g., assessing anxiety, depression,
empathy, emotion regulation, positive and negative emotions), or as
they allow to assess different aspects of sleep quality, lifestyle, well-
being, prosociality, loneliness, social support and quality of life.
Questionnaires are also proposed to a partner (i.e., a participant’s close
relative or friend) to assess how the partner perceives the mindfulness,
compassion, depression, anxiety, and prosocialness of the participant
as well as questions on the social support and the role ofan informal
carer of the partner.
Composite scores and raw individual measures of cognitive performance,
well-being, mindfulness and meta-cognition, emotion-related
questionnaires, altruism, prosociality, sleep quality, lifestyle, and quality
of life of the participants. Partner perception of the participant’s
mindfulness, compassion, depression, anxiety, and prosocialness as well
as questions on the social support and the role of an informal carer of the
partner.
Neuroimaging measures (Supplementary Table 2 for details):
1) Structural MRI
a) 3D T1 and fluid-attenuated inversion recovery—FLAIR
b) High-resolution proton-density focused on the hippocampus
c) Diffusion Kurtosis Imaging—DKI
d) Quantitative Susceptibility Mapping—QSM
2) Functional MRI—fMRI
a) Resting-state fMRI
b) Task-related fMRI
i) The AX-CPT task [30]
ii) The SoVT-Rest task
3) Resting-state EEG
4) Auditory event-related potential (ERP) using a mismatch negativity
protocol sensitive to aging [31]
5) PET scans
a) FDG (Glucotep) PET scan
b) Florbetapir (AV45, Amyvid) PET scan
- Gray and white matter volumes
- White matter lesions (number and size per type and location)
- Hippocampal subfield volumes
- Fractional anisotropy and mean diffusivity
- Magnetic susceptibility index
- Brain functional connectivity
- Behavioral and brain activity measures associated with attentional
processes (alertness, inhibition, sustained attention)
- Behavioral and brain activity and connectivity changes associated
with emotions and emotional inertia
- Resting-state spontaneous oscillatory activity
- ERP measures of brain activity associated with auditory mismatch
negativity
- Resting-state brain glucose consumption
- Brain perfusion from early florbetapir-PET acquisition
- Brain amyloid load from late florbetapir-PET acquisition
Biological measures from blood (Supplementary Table 3 for details):
Fasting sampling performed in the morning and after one day of diet
excluding ich food (tomatoes, avocados, pineapple, chocolate,
bananas.). 18 tubes (68 mL) of blood collected at V1 and 16 tubes
(62 mL) at V3.
- Global health: blood count, glucose, cholesterol/lipid profile, urea,
creatinine, Gamma-GlutamylTransferase, Glutamic Oxaloacetic
Transaminase, Glutamic Pyruvic Transaminase, Brain Natriuretic
Peptide, Thyroid Stimulating Hormone,
- Stress/inflammation: high-sensible C-Reactive Protein, cytokines,
cortisol, Superoxide Dismutase
- Aging/AD (telomere length, telomerase activity, b-amyloid (Ab)
1-40/42, Total Tau, Phospho-Tau, tissue Plasminogen Activator,
Plasminogen Activator Inhibitor-1, Brain Derived Neurotrophic
Factor, insulin, Insulin Growth Factor-1, lymphocyte
immunophenotyping, Repressor Element 1-Silencing Transcription
factor, Neurofilament,
- Mood: serotonin,
- Sex/gender: bioavailable testosterone, estradiol, Sex Hormone Bind-
ing Globulin, DeHydroEpiAndrosterone Sulfate
- Genetic: Apolipoprotein E, Genome Wild Association Study
- Epigenetics
Objective measures of sleep:
1) 1-week wrist actigraphy recording
2) 2-nights at-home polysomnography with 2D-object location task
performed before and after night sleep
3) 5-nights recording with Somno-Art
- Indices of mean sleep duration, sleep fragmentation and regularity of
the rest-activity cycle
- Multiple indices of sleep quality derived from EEG analyses and
behavioral measures of overnight memory consolidation
- Indices of night-to-night variability of sleep quality and quantity.
More details can be found in the Supplementary Material.
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four comparisons, with 80% power and a two-sided type I er-
ror of 1.25% (Bonferroni correction for test multiplicity), 42participants per arm (126 in total) need to be included. The
total number of participants included in the Age-Well RCT
(n 5 137) is higher than this required minimum of 126.
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The planned statistical analyses are detailed in a statistical
analysis plan and summarized in the Supplementary Material.
Briefly, statistical analyses related to the primary outcome
will be conducted on an intent-to-treat principle and missing
primary endpoint data will be handled with a “missing
5 failure” strategy. Additional analyses conducted on both pri-
mary and secondary outcomeswill include sensitivity analyses,
per-protocol analyses and analyses of exposure/dose effects.
2.6. Ethics, safety, and study monitoring
The Age-Well RCT was approved by the ethics commit-
tee (Comite de Protection des Personnes CPP Nord-Ouest
III, Caen; trial registration number: EudraCT: 2016-
002441-36; IDRCB: 2016-A01767-44; ClinicalTrials.gov
Identifier: NCT02977819) and adheres to Standard Protocol
Items: Recommendations for Interventional Trials guide-
lines for clinical trial protocols [36].
The management structure of Medit-Ageing is illustrated
in Fig. 3 and includes the coordinator (G.C.), the executive
committee and 9 work packages (including the management
work package). In addition, the sponsor (Inserm) has estab-
lished a trial steering committee in line with Good Clinic
Practice guidelines, and an external Data and Safety Moni-
toring Board, independent of the sponsor, was appointed.
More details on ethics and safety, study governance and
monitoring, as well as study progress can be found in the
Supplementary Material.
2.7. Clinical trial progress
From May 2016 to May 2018, about 900 individuals
came to public conferences and filled in the online prescre-Fig. 3. Management structening questionnaire. Among those, 157 participants were
screened. Thirteen did not fulfill the inclusion criteria (the
main reason being abnormal performance in the diagnostic
battery), 6 participants were excluded during V1 because
of artifacts or claustrophobia attack during the MRI scan
or high level of glycemia and 1 participant withdrew. Finally,
137 participants (40/60% men/women) were randomized to
the three experimental groups. Participants from the first and
second cohort had their 9-month intermediate follow-up
visit—at that time only 1 participant dropped out (death).
The 18-month follow-up post-intervention visits will end
in early 2020. Electronic data entry, monitoring and process-
ing are currently ongoing.3. Discussion
Age-Well is the first RCT to comprehensively assess the
long-term efficacy of meditation on well-being and aging
through a multidisciplinary approach. The strength and orig-
inality of the Age-Well RCT relies, first, in the nature, dose
and duration of the proposed interventions. Thus, this medi-
tation intervention is especially designed to target not only
cognitive control via the regulation of attention, but also psy-
choaffective factors through the reduction of stress and the
cultivation of positive emotions. This is crucial as stress,
anxiety and depression significantly contribute to reduced
quality of life and increased risk for dementia in older adults
[2]. Current lifestyle preventive trials tend to include multi-
domain interventions as recommended [6] but most often do
not focus on the emotional dimension of aging; thus they
target the main risk factors for dementia (cardiovascular
risk, diet, cognitive and physical activity) except the psy-
choaffective ones (e.g., depression). Moreover, interventionsure of Medit-Ageing.
G. Poisnel et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 714-723 721in Age-Well includeweekly 2-h group practice monitored by
highly experienced teachers and daily individual home prac-
tice collected over the 18 months of the interventions. They
might have the potential to induce long-term effects on brain
and biological markers of healthy aging.
Second, the Age-Well RCTassesses a wide range of com-
plementary outcomes including cognitive tests, scales and
questionnaires assessing well-being, quality of life, psy-
choaffective factors and lifestyle, but also complementary
MRI and positron emission tomography neuroimaging mea-
sures of brain structural and functional integrity, emotion and
attention-related neural activity, biological blood measures
and gold-standard measures of sleep with polysomnography.
In addition to being useful to provide a comprehensive over-
view of the effects and to monitor the effectiveness of the
intervention [6], this multidisciplinary approach will allow
for the investigation of mechanisms underlying the possible
effects of the intervention. A better understanding of the
mechanisms of action of meditation will facilitate sensitivity
to intervention analysis and help refine and tailor future
meditation-based interventions. The Age-Well RCT is mono-
centric thus avoiding intersite variability, which often limits
the inclusion of certain biomarkers in multisite clinical trials.
A further strength of this study to estimate specificmedita-
tion effects is the ability to use the foreign language interven-
tion as an active control condition. Many of the previous
studies of mindfulness-based interventions have suffered
from a lack of an adequate comparison condition. As
mindfulness-based interventions contain a number of non-
specific elements, such as social interaction, light exercise,
or the provision of treatment expectancies, the use of an active
control condition is important. Foreign language training was
selected as the active control condition for several reasons.
Like meditation, it involves cognitive mental training. It can
easily be matched structurally to the meditation intervention
(e.g., group sessions and daily practices with audio and video
supports). Positive effects are expected given that the learning
of a new language has been shown to impact on cognitive
functions and brain structures sensitive to aging and AD
[33,34]. In addition to being useful as an active control
condition, this intervention has its own scientific interest as
the first RCT to date on language training in older adults
over 18 months and with multidisciplinary outcomes
including multimodal neuroimaging. Note that, while both
interventions are expected to have a positive impact in
aging populations, they are expected to target distinct
aspects ofmental health andwell-being and to involve distinct
mechanisms (Fig. 1). In particular, foreign language training
is not expected to directly impact on emotional states, con-
trary to meditation training. It will thus be interesting to
compare the relative effects of both interventions on the
different outcome measures.
As for the choice of the primary endpoint, most previous
long-term preventive trials used clinical/cognitive measures.
Here we think that the use of neuroimaging biomarker is
more appropriate as we are interested in the earliest stageswhere clinical and cognitive decline is not expected to be sig-
nificant within 18 months, while neuroplasticity is likely to
occur and be translated in measurable brain changes. Neuro-
imaging biomarkers are increasingly used in ongoing trials,
especially in preventive trials or early disease stages and
when the goal is to show an effect on the pathophysiology
of the disease [37]. More specifically, the ACC and insula
emerge as the most appropriate endpoints for the following
reasons: the ACC is both i) a brain area with known relevance
to maintain cognitive function in older people [36–39] and ii)
one of the brain regions most sensitive to meditation [20,22].
The insula has been selected to assess the effects of the
meditation intervention compared with the foreign language
training intervention as it is a region related to interoceptive
awareness, emotional and empathic processing, also most
frequently involved in meditation studies [20,22] but less
likely to be involved in cognitive training and to be
impacted by the foreign language training intervention.
A side effect of most clinical studies and especially those
that are highly demanding (in terms of examinations and
intervention), is that individuals interested in participating
are likely to be particularly active and educated. They might
thus not be representative of the general population. Future
studies should develop specific strategies to stimulate enroll-
ment of under-represented populations in such clinical trials
and increase generality of findings. In addition, the Age-
Well RCT is interested in assessing the effects of the inter-
ventions on brain structure and function and investigating
the mechanisms underlying these effects. Future studies
could focus on estimating impact on clinical outcomes
such as conversion to mild cognitive impairment or dementia
using comparative trials with a sufficient duration of
follow-up.
The results of the Age-Well RCT are expected to further
the understanding of the factors preventing and delaying
age-related diseases and disabilities to promote healthy aging
and older adults’ well-being and to propose innovative thera-
peutic approaches. Our objectives are expected to reduce
stress, to improve the maintenance of cognitive abilities and
the regulation of emotion in older adults through meditation
practice, to establish a preventive strategy favoring the
emotional dimension of healthy aging and to reduce the nega-
tive impact ofmental conditions and disorders. TheAge-Well
RCT, andMedit-Ageing at large, should help shape and opti-
mize future lifestyle-based and meditation-based clinical tri-
als and facilitate the integration of meditation practice into
existing and future prevention programs and clinical interven-
tions in older people. Future trialswould be needed to confirm
the long-term clinical impact on aging populations.Acknowledgments
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1. Systematic review: We reviewed previously pub-
lished literature and existing randomized controlled
trials (RCTs) in the fields of aging, prevention of de-
mentia or Alzheimer’s disease, and nonpharmaco-
logical interventions from PubMed and
clinicaltrials.gov. Previous RCT-evaluated individu-
alized programs of physical activities or technology-
based solutions to improve the quality of life of older
people. The largest ongoing nonpharmacological
prevention RCT use multidomain interventions
simultaneously targeting various vascular and
lifestyle-related risk factors.
2. Interpretation: Age-Well is the first RCT in aging to
propose a long-term intervention addressing the
plasticity of emotional and cognitive dimensions
during aging. It will assess the effects and mecha-
nisms of a long-term meditation-based intervention
compared with a foreign language training and a
passive control condition on behavioral, neuro-
imaging, sleep and biological blood markers of
mental health and well-being in the aging population.
3. Future directions: The Age-Well clinical trial might
facilitate the integration of meditation practice and
foreign language learning into existing and future pre-
ventive programs in older people and contribute to the
design of larger multinational prevention RCTs.References
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